Independent Study Shows ERNA-101 Combo Clears Tumors in 67% of Ovarian Cancer Models
ERNA has more than doubled off its 52-week low of $3.183.
Summary
An independent CRO reproduced and expanded earlier preclinical results for Ernexa's lead cell therapy ERNA-101. The combination with anti-PD-1 achieved complete tumor clearance and durable survival in 10 of 15 animals (67%), while no complete responses occurred in any monotherapy or control arm. This third-party validation in a larger study strengthens the scientific case ahead of the planned IND submission this quarter. The company remains on track for a first-in-human Phase 1 trial in Q4 2026. With a market cap near $7M and tight liquidity, positive data that de-risks the lead program is material. The news follows a series of preclinical updates and the recent shareholder approval of an equity incentive plan, underscoring the company's push toward the clinic.
At the time of this announcement, ERNA was trading at $11.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.1M. The 52-week trading range was $3.18 to $71.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.